Today, two major US companies associated with the medical-insurance (UnitedHealth) and medical (Johnson&Johnson) markets reported financial results for Q1 2024. Both companies reported higher-than-expected earnings, but it was UnitedHealth's (UNH.US) report that came as the bigger positive surprise, while Johnson&Johnson's (JNJ.US) results suggest lower demand in the MedTech sector. Both companies are listed members of the Dow Jones Industrial Average (DIJA) index.
UnitedHealth with a positive surprise
Despite the February 2024 cyber-attack, the company expects to achieve its previously set annual sales targets, to which the market reacted optimistically. Shares are gaining more than 4% in the pre-market. Revenues rose almost 9% from $91.9bn in Q1 2023 to $99.8bn in Q1 2024. Adjusted earnings per share came in at US$6.91 against US$6.61 forecasts.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile app- The negative currency effect from the sale of the company's Brazil unit and the cyberattack weakened earnings per share by US$1.53 (US$0.74 due to the cyberattack and expected from US$1.15 - US$1.35 for the full year horizon). MCR was 84.3% compared to 83.8% expected on Wall Street, indicating a continuing problem with achieving full profitability.
- Pharmaceutical services sales and consulting at the Optum unit (103m customers) were $61.1bn vs $54.1bn in Q1 .2023. Medical services sales offered at UnitedHealthCare were $75.3bn vs $70.5bn in Q1 .2023, the company indicated, driven by healthy private client growth (up 2m in Q1 .2024). The company expects adjusted earnings per share of US$27.5 to US$28 in 2024.
United Health (UNH.US) chart, D1 interval
Source: xStation5
Johnson&Johnson's adjusted EPS came in at US$2.71 against US$2.65, and sales of US$21.38bn came in marginally lower than the US$21.39bn forecast. Medical technology sales came in at US$7.82bn against US$7.94bn expectations, and the company's full-year sales estimates are now oscillating between US$88bn and US$88.4bn, indicating that the company expects a slight improvement in revenue, in future quarters. The company's shares are trading flat ahead of the US market open.
Johnson&Johnson (JNJ.US) chart, D1 interval
Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
